



## NASH and Systemic Complications: From Basic to Clinical Research

Guest Editors:

**Prof. Dr. Ronit Shiri-Sverdllov**

NUTRIM, Department of  
Molecular Genetics, Maastricht  
University, Maastricht, The  
Netherlands

**Dr. Sabine Baumgartner**

Department of Nutrition and  
Movement Sciences, Maastricht  
University, Maastricht, The  
Netherlands

Deadline for manuscript  
submissions:

**closed (31 January 2021)**

### Message from the Guest Editors

Dear colleagues,

High intake of sugar- and fat-enriched meals and low physical activity has led to an increase in NAFLD both in adults and in children. Whereas most of the patients develop simple fat accumulation, up to one-third is also affected with inflammation in the liver (NASH). NASH is considered a global health threat. However, the gold standard for diagnosing NASH is an invasive liver biopsy and therapeutic options to cure NASH do not exist, implying the urgent need for better understanding its underlying mechanisms.

This Special Issue intends to shed light on the pathophysiology, clinical problems, diagnostic methods, therapeutic approaches and lifestyle adaptations of NASH as well as on its systemic effects, including cardiovascular diseases, type 2 diabetes, cancer and chronic kidney disease. Our overall aim is to create awareness of the opportunities and challenges in translational NASH and to the fact that NASH patients can benefit from a multidisciplinary evaluation. We encourage all researchers and clinicians in these fields to share their novel findings, interpretations and ideas.

Prof. Dr. Ronit Shiri-Sverdllov

Dr. Yvonne Oligschläger

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)